Pluristem Therapeutics Inc. (NASDAQ:PSTI): Closing price $3.36
Pluristem announced that its placental expanded cells were proved safe in an animal study examining maternal and fetal toxicity. The study was run at the Charles River Laboratories, a top contract research organization. The results indicated that the intramuscular administration of PLX-PAD cells to pregnant rats did not result in any maternal or fetal toxicity. Pluristem will follow the clinical development of PLX-PAD cells for the indication of preeclampsia, based on these results and earlier evidence that the cells were efficacious in preeclamptic animal models.
WuXi PharmaTech Inc. (NYSE:WX): Current price $30.76
Wuxi Pharms reported a licensing agreement Monday with Mayo Clinic’s Center for Individualized Medicine, through which to expand WuXi’s collection of patient-derived xenograft mouse models. These models should support the cancer drug discovery and personalized medicine endeavors of WuXi’s worldwide customers. Through the terms, WuXi has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries, which have been developed in conjunction with the center’s research and patient care. Wuxi is a pharmaceutical, biotechnology, and medical device research and development outsourcing firm having operations in China and the United States.
Harvard Bioscience Inc. (NASDAQ:HBIO): Closing price $4.42
On Friday, Harvard Bioscience became a pure-play global developer, maker and marketer of a wide range of tools to advance life science research. This development came about whenthe previously announced spin-off of its former wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, was completed as of 12:01 a.m. on that date. The spin-off was achieved via the distribution to Harvard Bioscience’s shareholders of one share of HART common stock for every four shares of Harvard Bioscience stock held at the close on the record date of October 21.
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN): Closing price $2.70
Achillion has announced a poster presentation outlining the preclinical profile of ACH-3422, its uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection. The poster is being presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases in Washington D.C.
Don’t Miss: Who’s Making Money Off the Marijuana Gold Rush?